Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392. https://doi.org/10.1001/archneur.60.3.387

Article  PubMed  Google Scholar 

Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in parkinson’s disease. Mov Disord 20:1255–1263. https://doi.org/10.1002/mds.20527

Article  PubMed  Google Scholar 

Alzahrani H, Venneri A (2018) A cognitive rehabilitation in parkinson’s disease: a systematic review. J Park Dis 8:233–245. https://doi.org/10.3233/JPD-171250

Article  Google Scholar 

Anang JB, Gagnon JF, Bertrand JA et al (2014) Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83:1253–1260. https://doi.org/10.1212/WNL.0000000000000842

Article  PubMed  PubMed Central  Google Scholar 

Anand S, Schoo C (2024) Mild cognitive impairment. StatPearls Publishing. Retrieved April 4, 2025, from http://www.ncbi.nlm.nih.gov/books/NBK599514

Andersen AD, Binzer M, Stenager E, Gramsbergen JB (2017) Cerebrospinal fluid biomarkers for parkinson’s disease - a systematic review. Acta Neurol Scand 135:34–56. https://doi.org/10.1111/ane.12590

Article  CAS  PubMed  Google Scholar 

Baba T, Hosokai Y, Nishio Y et al (2017) Longitudinal study of cognitive and cerebral metabolic changes in parkinson’s disease. J Neurol Sci 372:288–293. https://doi.org/10.1016/j.jns.2016.11.068

Article  CAS  PubMed  Google Scholar 

Ballard C, Zahn Z, Corbett A (2011) Treatment of dementia with lewy bodies and parkinson’s disease dementia. Drugs Aging 28:769–777. https://doi.org/10.2165/11594110-000000000-00000

Article  CAS  PubMed  Google Scholar 

Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D (2011) Cognitive impairment in nondemented parkinson’s disease. Mov Disord 26:2483–2495. https://doi.org/10.1002/mds.23919

Article  PubMed  Google Scholar 

Bayram E, Batzu L, Tilley B et al (2023) Clinical trials for cognition in parkinson’s disease: where are we and how can we do better? Parkinsonism Relat Disoder 112:105385. https://doi.org/10.1016/j.parkreldis.2023.105385

Article  Google Scholar 

Bianchi ML, Riboldazzi G, Mauri M, Versino M (2019) Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic parkinson’s disease. Neurol Sci 40:275–279. https://doi.org/10.1007/s10072-018-3628-3

Article  PubMed  Google Scholar 

Booth S, Park KW, Lee CS, Ko JH (2022) Predicting cognitive decline in parkinson’s disease using FDG-PET-based supervised learning. J Clin Invest 132:e157074. https://doi.org/10.1172/JCI157074

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brandão PR, Munhoz RP, Grippe TC et al (2020) Cognitive impairment in parkinson’s disease: a clinical and pathyphysiological overview. J Neurol Sci 419:117177. https://doi.org/10.1016/j.jns.2020.117177

Article  PubMed  Google Scholar 

Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022. https://doi.org/10.1212/01.wnl.0000306632.43729.24

Article  CAS  PubMed  Google Scholar 

Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:176. https://doi.org/10.1038/s41419-023-05672-9

Article  PubMed  PubMed Central  Google Scholar 

Compta Y, Parkkinen L, O’Sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in parkinson’s disease dementia: which is more important? Brain J Neurol 134:1493–1505. https://doi.org/10.1093/brain/awr031

Article  Google Scholar 

Cools R, D’Esposito M (2011) Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatr 69:e113–e125. https://doi.org/10.1016/j.biopsych.2011.03.028

Article  CAS  Google Scholar 

Domellöf ME, Ekman U, Forsgren L, Elgh E (2015) Cognitive function in the early phase of parkinson’s disease: a five-year follow up. Acta Neurol Scand 132:79–88. https://doi.org/10.1111/ane.12375

Article  PubMed  Google Scholar 

Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with parkinson’s disease. Mov Disord 22:1689–1707. https://doi.org/10.1002/mds.21507

Article  PubMed  Google Scholar 

Frost ED, Shi SX, Byroju VV et al (2024) Galanatamine-memantine combination in the treatment of parkinson’s disease dementia: a systematic review and meta-analysis. Brain Sci 14:1163. https://doi.org/10.3390/brainsci14121163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Garcia D, Clavero P, Gasca Salas S et al (2012) Posterior parietooccipital hypometabolism May differentiate mild cognitive impairment from dementia in parkinson’s diseae. Eur J Nucl Med Mol Imaging 39:1767–1777. https://doi.org/10.1007/s00259-012-2198-5

Article  PubMed  Google Scholar 

Gibson LL, Weintraub D, Lemmen R et al (2024) Risk of dementia in parkinson’s disease: a systematic review and meta-analysis. Mov Disord 39:1697–1709. https://doi.org/10.1002/mds.29918

Article  CAS  PubMed  Google Scholar 

Gratwicke J, Jahanshahi M, Foltynie T (2015) Parkinson’s disease dementia: a neural networks perspective. Brain J Neurol 138:1454–1476. https://doi.org/10.1093/brain/awv104

Article  Google Scholar 

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844. https://doi.org/10.1002/mds.21956

Article  PubMed  Google Scholar 

Hietanen M, Teräväinen H (1986) Cognitive performance in early parkinson’s disease. Acta Neurol Scand 73:151–159. https://doi.org/10.1111/j.1600-0404-1986.tb03257.x

Article  CAS  PubMed  Google Scholar 

Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745. https://doi.org/10.1212/WNL.0b013e3181c34b47

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kehagia AA, Barker RA, Robbins TW (2013) Cognitive impairment in parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis 11:79–92. https://doi.org/10.1159/000341998

Article  PubMed  Google Scholar 

Litvan I, Aarsland D, Adler C et al (2011) MDS task force on mild cognitive impairment in parkinson’s disease: critical review of PD-MCI. Mov Disord 26:1814–1824. https://doi.org/10.1002/mds.23823

Article  PubMed  PubMed Central  Google Scholar 

Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27:349–356. https://doi.org/10.1002/mds.24893

Article  PubMed  PubMed Central  Google Scholar 

Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 38:937–945. https://doi.org/10.1007/s11055-008-9077-3

Article  CAS  PubMed  Google Scholar 

Lorenz R, Samnick S, Dillmann U et al (2014) Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson’s disease. Acta Neurol Scand 130:164–171. https://doi.org/10.1111/ane.12259

Article  CAS  PubMed  Google Scholar 

Mantovani E, Martini A, Dinoto A et al (2024) Biomarkers for cognitive impairment in alpha synucleinopathies: an overview of systemative reviews and meta-analyses. NPJ Park Dis 10:211.